CN1711092A - 抗过敏剂和类固醇用于治疗过敏性鼻炎的用途 - Google Patents

抗过敏剂和类固醇用于治疗过敏性鼻炎的用途 Download PDF

Info

Publication number
CN1711092A
CN1711092A CNA2003801029346A CN200380102934A CN1711092A CN 1711092 A CN1711092 A CN 1711092A CN A2003801029346 A CNA2003801029346 A CN A2003801029346A CN 200380102934 A CN200380102934 A CN 200380102934A CN 1711092 A CN1711092 A CN 1711092A
Authority
CN
China
Prior art keywords
steroid
compositions
right amount
olopatadine
allergic rhinitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2003801029346A
Other languages
English (en)
Other versions
CN1297275C (zh
Inventor
G·D·卡格尔
G·M·沃尔
J·M·扬尼
R·贾尼
H·G·巴哈盖特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of CN1711092A publication Critical patent/CN1711092A/zh
Application granted granted Critical
Publication of CN1297275C publication Critical patent/CN1297275C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

本发明披露了用于治疗鼻炎的含有某些抗过敏剂和类固醇组合的组合物和用其治疗鼻炎的方法。

Description

抗过敏剂和类固醇用于治疗过敏性鼻炎的用途
本发明涉及抗过敏剂和类固醇组合用于治疗鼻部病症、尤其是鼻炎的用途。
发明背景
过去一直用口服抗组胺药和/或口服类固醇的方案治疗过敏性鼻炎。全身性治疗通常要求所施用的药物化合物具有更高浓度以便使有效的浓度到达必要的治疗部位。已知抗组胺化合物具有中枢神经系统(CNS)活性，表现为嗜睡。它们还具有抗胆碱能活性，表现为粘膜发干。
鼻内组合治疗是已知的。例如，WO 97/01337披露了用于治疗鼻炎的局部鼻用抗组胺药和局部鼻用类固醇的组合。但是该专利没有披露本发明的抗过敏剂和类固醇组合的用途。WO 97/46243披露了含有类固醇和抗组胺药的鼻腔喷雾剂。但是该专利也没有披露本发明的组合。在美国境外有含类固醇和抗组胺药的鼻内产品上市销售，例如：Pharmacobel的Cortinasal，其含有安他心和氢化可的松；SmithKline Beecham的Rinosular，其含有苯海拉明和泼尼松龙；以及AlconCusi的Rinocusi，其含有苯海拉明和氢化可的松。
发明概述
本发明涉及用于治疗鼻炎的含有某些抗过敏剂和类固醇组合的鼻内组合物。所述的抗过敏剂选自依美司汀或奥洛他定。所述的类固醇选自氟地松、莫美达松、布地缩松或倍氯米松。本发明还涉及在哺乳动物中使用所述组合物的方法。
优选实施方案描述
本发明包括依美司汀或奥洛他定和所选择的类固醇的组合物，所述组合物用于治疗与过敏性鼻炎有关的喷嚏、鼻液溢、充血和瘙痒。
依美司汀和奥洛他定是已知的抗过敏化合物。依美司汀在美国专利No.4,430,343中有披露。奥洛他定在美国专利No.5,116,863中有披露；其用于治疗眼科过敏性病症的用途在美国专利No.5,641,805中有披露。本发明的组合物中抗过敏剂的浓度为0.01-0.8％(w/v)，优选地，奥洛他定的浓度为0.1-0.8％(w/v)，依美司汀的浓度为0.01-0.1％(w/v)。依美司汀优选以二富马酸依美司汀形式被加入本发明的组合物中。奥洛他定优选以盐酸奥洛他定形式被加入。
本发明的组合产品包含选自以下的类固醇：氟地松、莫美达松、布地缩松和倍氯米松。已知这些类固醇中的每一种均用于治疗鼻炎。本发明的组合物中类固醇的浓度为0.01-1.0％(w/v)，优选为0.02-0.5％(w/v)。优选地，氟地松以丙酸氟地松形式被加入本发明的组合物中，莫美达松以糠酸莫美达松一水合物形式被加入，倍氯米松以二丙酸倍氯米松形式被加入。在一个实施方案中，用已知技术调整类固醇的大小以便使其具有2.5-5μm的平均粒度。在另一个实施方案中，用已知的纳米化技术获得了平均粒度小于0.8μm、优选0.5μm或更小的类固醇颗粒。
本发明中的组合可被掺入多种用于向鼻递送的鼻内制剂中。例如，制剂可以采用被设计作为气雾剂、水性喷雾剂或滴剂施用的溶液或混悬液形式。优选地，制剂是被包装成鼻腔喷雾剂的水性组合物。给药方案可根据熟练临床医生的常规考虑来确定，但通常是将1至2喷的这些制剂递送至鼻孔，每天不超过两次，每喷递送25-100μL制剂。
除了抗过敏剂和类固醇之外，制剂还可以含有鼻用制剂领域中已知的赋形剂，包括抗微生物剂、抗氧化剂、增粘剂、张力调节剂、缓冲剂、增溶剂、表面活性剂等。例如，水性鼻内制剂可以含有防腐剂和防腐辅剂，如季铵类防腐剂例如苯扎氯铵和聚季铵盐-1(Polyquaternium-1)以及EDTA；粘度调节剂，如羟丙基甲基纤维素(HPMC)、聚乙烯吡咯烷酮和羧甲基纤维素；张力调节剂，如氯化钠、氯化钾、甘露醇、山梨醇和甘油；湿润剂/表面活性剂，如四丁酚醛或聚山梨酯80；以及pH调节剂，如NaOH或HCl。本发明的制剂中季铵类防腐剂的量通常为0.001-0.03％(w/v)。本发明的组合物优选被配制成具有约3.5-8.0的pH和1-50cps的粘度。
以下实施例是本发明的组合物的举例说明，但绝不限制本发明。
                 实施例1
  成分   ％(w/v)
  二富马酸依美司汀   0.05
  丙酸氟地松   0.05
  苯扎氯铵   0.001-0.03
  EDTA二钠   0.01
  氯化钠(调节张力至250-350mOsmols/kg)   0.1-0.8
  HPMC   0.1-0.5
  四丁酚醛   0.05
  氨基丁三醇   0.5
  NaOH和/或HCl   适量至pH4-7.7
  纯化水   适量至100
                 实施例2
  成分   ％(w/v)
  奥洛他定   0.4-0.6
  丙酸氟地松   0.05
  苯扎氯铵   0.001-0.03
  聚维酮K-29/32   1.8
  EDTA二钠   0.01
  氯化钠(调节张力至250-350mOsmols/kg)   0.1-0.8
  四丁酚醛   0.05
  磷酸氢二钠   0.5
  NaOH和/或HCl   适量至pH4-7.7
  纯化水   适量至100
                 实施例3
  成分   ％(w/v)
  奥洛他定   0.4-0.8
  丙酸氟地松   0.05
  苯扎氯铵   0.001-0.03
  磷酸氢二钠   0.5
  EDTA二钠   0.01
  氯化钠(调节张力至250-350mOsmols/kg)   0.6-0.8
  四丁酚醛   0.05
  NaOH和/或HCl   适量至pH4-7.7
  纯化水   适量至100
                 实施例4
  成分   ％(w/v)
  奥洛他定   0.4-0.6
  丙酸氟地松   0.05
  聚季铵盐-1   0.001-0.03
  聚维酮K-29/32   1.8
  EDTA二钠   0.01
  甘露醇(调节张力至250-350mOsmols/kg)   0.5-5
  四丁酚醛   0.05
  硼酸   0.5
  NaOH和/或HCl   适量至pH4-7.7
  纯化水   适量至100
                 实施例5
  成分   ％(w/v)
  奥洛他定   0.4-0.8
  丙酸氟地松   0.05
  聚季铵盐-1   0.001-0.03
  磷酸氢二钠   0.5
  EDTA二钠   0.01
  氯化钠(调节张力至250-350mOsmols/kg)   0.1-0.8
  硼酸   0.5
  四丁酚醛   0.05
  NaOH和/或HCl   适量至pH4-7.7
  纯化水   适量至100
                                       实施例6
                            奥洛他定和类固醇的鼻腔喷雾制剂
  制剂   1   2   3   4   5   6   7   8   9   10
  成分                                                        ％(w/v)
  盐酸奥洛他定   0.665   0.665   0.665   0.665   0.665   0.665   0.665   0.665   0.665   0.665
  丙酸氟地松   0.05   0.05   0   0   0.05   0   0.05   0   0.05   0
  布地缩松   0   0   0.03   0.03   0   0.03   0   0.03   0   0.03
  聚维酮   1.8   0.5   1.8   0.5   0   0   1.0   1.0   0   0
  微晶纤维素   0   0   0   0   0.9   0.9   0   0   0.9   0.9
  羧甲基纤维素钠   0   0   0   0   0.1   0.1   0   0   0.1   0.1
  苯扎氯铵   0.001-0.03   0.001-0.03   0.001-0.03   0.001-0.03   0.001-0.03   0.001-0.03   0.001-0.03   0.001-0.03   0.001-0.03   0.001-0.03
  四丁酚醛   0   0   0   0   0   0   0.05   0.05   0.05   0.05
  聚山梨酯80   0.005   0.005   0.005   0.005   0.005   0.005   0   0   0   0
  磷酸氢二钠，无水   0.5   0.5   0.5   0.5   0.5   0.5   0.5   0.5   0.5   0.5
  氯化钠   适量至250-350mOsm/kg  适量至250-350mOsm/kg   适量至250-350mOsm/kg  适量至250-350mOsm/kg  适量至250-350mOsm/kg  适量至250-350mOsm/kg   适量至250-350mOsm/kg  适量至250-350mOsm/kg   适量至250-350mOsm/kg  适量至250-350mOsm/kg
  依地酸二钠   0.01   0.01   0.01   0.01   0.01   0.01   0.01   0.01   0.01   0.01
  NaOH/HCl   适量至pH4-7.7   适量至pH4-7.7   适量至pH4-7.7   适量至pH4-7.7   适量至pH4-7.7   适量至pH4-7.7   适量至pH4-7.7   适量至pH4-7.7   适量至pH4-7.7   适量至pH4-7.7
  纯化水，适量至   100   100   100   100   100   100   100   100   100   100

Claims (10)

1.治疗哺乳动物的过敏性鼻炎的方法，该方法包括施用药学有效量的包含选自依美司汀和奥洛他定的抗过敏剂和选自氟地松、莫美达松、布地缩松和倍氯米松的类固醇的组合物。
2.权利要求1的方法，其中组合物中抗过敏剂的量为0.01-0.8％(w/v)，组合物中类固醇的量为0.01-1.0％(w/v)。
3.权利要求1的方法，其中抗过敏剂是奥洛他定。
4.权利要求3的方法，其中类固醇是氟地松。
5.权利要求1的方法，其中类固醇具有2.5-5μm的平均粒度。
6.权利要求1的方法，其中类固醇具有小于0.8μm的平均粒度。
7.权利要求6的方法，其中类固醇具有0.5μm或更小的平均粒度。
8.权利要求1的方法，其中组合物是包装成鼻腔喷雾剂的水性组合物。
9.权利要求1的方法，其中组合物具有3.5-8.0的pH和1-50cps的粘度。
10.治疗哺乳动物的过敏性鼻炎的方法，该方法包括施用药学有效量的组合物，所述组合物包含0.1-0.8％(w/v)的奥洛他定和0.02-0.5％(w/v)的选自氟地松、莫美达松、布地缩松和倍氯米松的类固醇，其中组合物具有3.5-8.0的pH和1-50cps的粘度，且所述组合物是包装成鼻腔喷雾剂的水性组合物。
CNB2003801029346A 2002-11-12 2003-11-12 抗过敏剂和类固醇用于治疗过敏性鼻炎的用途 Expired - Fee Related CN1297275C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42549402P 2002-11-12 2002-11-12
US60/425,494 2002-11-12

Publications (2)

Publication Number Publication Date
CN1711092A true CN1711092A (zh) 2005-12-21
CN1297275C CN1297275C (zh) 2007-01-31

Family

ID=32312998

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801029346A Expired - Fee Related CN1297275C (zh) 2002-11-12 2003-11-12 抗过敏剂和类固醇用于治疗过敏性鼻炎的用途

Country Status (12)

Country Link
US (1) US20040097474A1 (zh)
EP (1) EP1560586A1 (zh)
JP (1) JP2006508138A (zh)
KR (1) KR20050074577A (zh)
CN (1) CN1297275C (zh)
AU (1) AU2003291497B2 (zh)
BR (1) BR0316203A (zh)
CA (1) CA2504200A1 (zh)
MX (1) MXPA05005044A (zh)
PL (1) PL376970A1 (zh)
WO (1) WO2004043470A1 (zh)
ZA (1) ZA200503243B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102018680B (zh) * 2009-09-18 2012-02-29 华北制药股份有限公司 一种富马酸依美斯汀缓释片及其制备方法
CN111787954A (zh) * 2018-02-23 2020-10-16 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎
CN112773808A (zh) * 2013-10-04 2021-05-11 格兰马克专业公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055152A1 (en) * 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
US20090235933A1 (en) * 2008-08-26 2009-09-24 Trutek Corp. Electrostatically charged mask filter products and method for increased filtration efficiency
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
PL373433A1 (en) * 2002-08-30 2005-08-22 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US20090317477A1 (en) * 2004-03-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20050227927A1 (en) * 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20050222049A1 (en) * 2004-03-31 2005-10-06 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
WO2006031848A2 (en) * 2004-09-15 2006-03-23 Ivax Corporation Corticosteroid topical dispersion with low content of surfactant
CN103860540A (zh) * 2004-11-24 2014-06-18 爱尔康公司 奥洛他定在治疗鼻子过敏或发炎状态的制剂制备中的用途
LT2486942T (lt) 2004-11-24 2019-01-25 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną ir jų panaudojimo būdai
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
US8497258B2 (en) * 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
ES2781090T3 (es) * 2007-02-07 2020-08-28 Novartis Ag Formulaciones de olopatadina para administración nasal tópica
US20100227917A1 (en) * 2007-09-06 2010-09-09 Masashi Nakakura EYE DROP CONTAINING DIBENZ[b,e]OXEPIN DERIVATIVE
KR20110036919A (ko) * 2008-07-07 2011-04-12 트루텍 코프. 정전기를 띤 비강 적용 다목적 제품 및 방법
KR20110056526A (ko) * 2008-08-28 2011-05-30 트루텍 코프. 항히스타민 및 유사-항히스타민 코 외용약, 생성물 및 방법
WO2011141929A2 (en) * 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
JP6203967B2 (ja) * 2013-09-13 2017-09-27 グレンマーク・スペシャルティー・エスエー モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
WO2021112242A1 (ja) * 2019-12-06 2021-06-10 東興薬品工業株式会社 ステロイド化合物およびオロパタジンを含有する医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3662944B2 (ja) * 1993-08-24 2005-06-22 協和醗酵工業株式会社 点鼻剤
JP3696265B2 (ja) * 1994-02-04 2005-09-14 日本オルガノン株式会社 点鼻液剤
WO1997001337A1 (en) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
WO1997046243A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
AU7859800A (en) * 1999-10-08 2001-04-23 Schering Corporation Topical nasal treatment
BR0015647A (pt) * 1999-11-18 2002-07-16 Alcon Inc Uso de um antagonista de h1 e um esteróide seguro para tratar condições dos olhos
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
BR0214643A (pt) * 2001-12-05 2004-11-03 Alcon Inc Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102018680B (zh) * 2009-09-18 2012-02-29 华北制药股份有限公司 一种富马酸依美斯汀缓释片及其制备方法
CN112773808A (zh) * 2013-10-04 2021-05-11 格兰马克专业公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
CN111787954A (zh) * 2018-02-23 2020-10-16 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎
CN111787954B (zh) * 2018-02-23 2023-09-05 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎

Also Published As

Publication number Publication date
CN1297275C (zh) 2007-01-31
BR0316203A (pt) 2005-10-04
AU2003291497B2 (en) 2007-12-20
WO2004043470A1 (en) 2004-05-27
US20040097474A1 (en) 2004-05-20
ZA200503243B (en) 2006-06-28
JP2006508138A (ja) 2006-03-09
AU2003291497A1 (en) 2004-06-03
MXPA05005044A (es) 2005-07-01
EP1560586A1 (en) 2005-08-10
KR20050074577A (ko) 2005-07-18
PL376970A1 (pl) 2006-01-23
CA2504200A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
CN1297275C (zh) 抗过敏剂和类固醇用于治疗过敏性鼻炎的用途
US8962601B2 (en) Pharmaceutical products and composition comprising specific anticholinergic agents, β-2 agonists and corticosteroids
EP2075000B1 (en) Combination of azelastine and ciclesonide
EP1174139B1 (en) Use of mometasone furoate for treating airway passage and lung diseases
US6297227B1 (en) Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US7022687B1 (en) Combination of loteprednol and antihistamines
CA2522292A1 (en) Nasal pharmaceutical formulations and methods of using the same
HU226527B1 (hu) Készítmények nátha kezelésére
CN110237260A (zh) 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
JP2012520882A5 (zh)
CA2495275A1 (en) Aerosol formulation for inhalation comprising an anticholinergic agent
EP1467762B1 (en) Use of a h1 antagonist and rimexolone as a safe steroid to treat rhinitis
CA2522291A1 (en) Nasal pharmaceutical formulations and methods of using the same
EP2201936B1 (en) Method of treating acute rhinosinusitis
JP2003523393A (ja) 呼吸器疾患治療用メタロプロティナーゼ阻害剤
JP2022520990A (ja) 呼吸器疾患の治療の方法
KR20050085104A (ko) 로플루미래스트와 포르모테롤을 포함하는 신규한상승작용성 조합물
RU2614716C2 (ru) Фармацевтическая композиция для применения назальным введением, содержащая кортикостероид и хинолон или фузидовую кислоту
WO2000015234A1 (en) Compositions comprising corticosteroids for treating sinusitis or otitis media

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070131

Termination date: 20141112

EXPY Termination of patent right or utility model